A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects

• Published in: Cancer chemotherapy and pharmacology 2020-05, Vol.85 (5), p.995-1001
• Main Authors: Ogasawara, Ken, Vince, Bradley, Xu, Christine, Zhang, Meng, Palmisano, Maria, Krishna, Gopal
• Format: Article
• Language: English
• Subjects: Adult; Antiemetics; Biological Availability; Cancer Research; Cross-Over Studies; Drug Interactions; Drug Monitoring - methods; Drug Therapy, Combination; Enzyme inhibitors; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - pharmacokinetics; Gastric juice; Healthy Volunteers; Humans; Janus kinase; Janus kinase 2; Janus Kinase 2 - antagonists & inhibitors; Kinases; Male; Medicine; Medicine & Public Health; Neutropenia; Oncology; Original Article; Pantoprazole - administration & dosage; Pantoprazole - adverse effects; Pantoprazole - pharmacokinetics; pH effects; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Prophylaxis; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - pharmacokinetics; Pyrrolidines - administration & dosage; Pyrrolidines - adverse effects; Pyrrolidines - pharmacokinetics; Solubility; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Treatment Outcome; Vomiting
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-020-04074-4

Purpose Fedratinib, an oral, selective Janus kinase 2 inhibitor with activity against both wild-type and mutant Janus kinase 2, has pH-dependent solubility, with free solubility at pH 1. Concomitant administration of drugs that reduce gastric acid secretion, such as pantoprazole, may decrease the absorption of fedratinib and affect patient outcomes. The aim of this study was to evaluate the impact of 7-day repeated 40-mg doses of pantoprazole on the pharmacokinetic (PK) properties of a single 500-mg dose of fedratinib in healthy male subjects. Methods In this phase I, single-center, open-label, two-period, two-treatment, fixed-sequence crossover study, healthy male subjects were administered a single dose of fedratinib 500 mg on day 1 in Period 1, followed by pantoprazole 40 mg daily for 7 days (day 1 to day 7) and a single dose of fedratinib 500 mg on day 7 in Period 2. After the discontinuation of nine subjects due to vomiting, the protocol was amended to provide ondansetron as antiemetic prophylaxis to an additional ten enrolled subjects. Results Twenty-six subjects were included. Repeated doses of pantoprazole 40 mg resulted in clinically insignificant increases in fedratinib exposure. Maximum plasma concentration increased by 1.09-fold and area under the plasma concentration–time curve from time 0 to infinity increased by 1.15-fold. All treatment-emergent adverse events were mild or moderate, except for one instance of neutropenia, which was considered unrelated to study intervention. Conclusion Coadministration with pantoprazole did not have clinically meaningful effects on fedratinib PK. No new or unexpected safety signals were observed with fedratinib.